Patient Case Studies of GvHD
Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.
EP: 1.Role of Allogeneic Transplants in Hematologic Malignancies
EP: 2.Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT
EP: 3.Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant
EP: 4.Transplant Complications and Survival Outcomes
EP: 5.Clinical Trial Update: CTN Trial
EP: 6.Graft-versus-Host Disease Prophylaxis and Management
EP: 7.Patient Case Studies of GvHD
EP: 8.Emerging Cellular Therapies in Hematologic Malignancies
EP: 9.Transplant in the Elderly Population
EP: 10.Toxicity Assessment of Precision-Engineered Allo-HSCT
EP: 11.The Role of Allo-HSCT in Higher-Risk MDS
EP: 12.Investigational Allo-HSCT for Advanced Hematologic Malignancies
EP: 13.The Future of Allo-HSCT and Cellular Therapies
EP: 14.OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion
This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.
The panel discusses the challenge of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which remains the leading cause of mortality in this setting. Regardless of the donor type, about 50% of patients who die after 100 days of allogeneic transplantation succumb to relapse. Prevention of relapse is crucial, as treatment options for post-transplant relapse are limited.
A Center for International Blood and Marrow Transplant Research study reported in 2015 showed that among 1800 patients who relapsed after allogeneic transplantation, only 30% achieved subsequent complete remission with chemotherapy, and these remissions were not durable. Patients who appeared to benefit in terms of survival were those who received a second allogeneic transplantation or donor lymphocyte infusion (DLI). However, only 17% of patients were candidates for a subsequent allogeneic transplantation.
The timing of relapse is a critical predictor of subsequent survival. Patients who relapse within the first 6 months have a 1-year survival of only 4%, while those who relapse after 2 or more years, particularly at 3 to 4 years, can be salvaged with subsequent cellular-based therapy, such as DLI or DLI followed by a second allogeneic transplantation, with 30% to 40% achieving long-term survival.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
